[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peripheral-vascular-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peripheral-vascular-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,51,83,113,137,170,199,230],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100604025","evero-drug-coated-balloon-dcb-randomized-trial-100604025",false,"NCT07144150","EVERO Drug-coated Balloon (DCB) Randomized Trial","Advance Evero™ 18 Everolimus-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter Versus Paclitaxel-coated Ballons in Patients With Femoropopliteal Disease (EVERO Trial)","Inclusion Criteria:\n\n1. Documented PAD with Rutherford classification 2 - 4; and\n2. De novo or restenotic (non-stented) target lesion located in the native superficial femoral artery (SFA), popliteal artery (P1 or P2), or both native SFA and popliteal arteries.\n\nExclusion Criteria:\n\nGeneral Exclusion Criteria\n\n1. Less than 18 years old;\n2. Inability or refusal to give informed consent by the patient or legally authorized representative;\n3. Life expectancy ≤ 12 months, per investigator assessment;\n4. Pregnant (or if absence of pregnancy is not verified by negative pregnancy test within 7 days of planned procedure), lactating, planning to become pregnant within 12 months of the planned procedure, or unwilling to use contraception for 12 months following the planned procedure;\n5. Unable or unwilling to comply with the follow-up schedule; or\n6. Simultaneously participating in another investigational drug or device study unless the patient is at least 30 days beyond the primary endpoint of any previous study.","ALL","18 Years",{"count":19,"type":20},410,"ESTIMATED","INTERVENTIONAL",[23],"NA","The primary objective of the study is to evaluate the long-term safety and effectiveness of the Advance Evero™ 18 Everolimus-coated Percutaneous Transluminal Angioplasty Balloon Catheter (hereafter referred to as the Evero drug-coated balloon \\[DCB\\]) in the treatment of the femoropopliteal artery lesions in patients with peripheral arterial disease (PAD). Specifically, the Randomized-Controlled Trial (RCT) is designed to demonstrate non-inferior safety and non-inferior effectiveness of the Evero DCB when compared to commercially available paclitaxel DCBs (pDCBs).",[26,27],"Peripheral Vascular Disease","Peripheral Arterial Disease",[29,30,31,32,33,34,35,36,37],"Intermittent claudication","Paclitaxel","Everolimus","Rapamycin","Drug-coated balloon (DCB)","Percutaneous transluminal angioplasty (PTA)","Femoropopliteal artery","Superficial femoral artery (SFA)","Popliteal artery","RECRUITING","2026-07-01",{"date":41,"type":42},"2026-07-02","ACTUAL",{"date":44,"type":42},"2026-04-17",{"date":46,"type":20},"2032-10",{"name":48,"class":49},"Cook Research Incorporated","INDUSTRY",5,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":21,"phases":62,"briefSummary":63,"conditions":64,"keywords":68,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100546818","enhancing-exercise-with-light-to-improve-functioning-in-pad-100546818","NCT06399900","ENhancing Exercise With LIGHT to Improve Functioning in PAD","ENhancing Exercise With LIGHT to Improve Functioning in PAD: the ENLIGHTEN PAD Trial","ENLIGHTEN PAD","Inclusion Criteria:\n\nFirst, all participants will be age 50 and older. Second, all participants will have PAD. PAD will be defined as:\n\n1. An ABI \\\u003C= 0.90 at baseline.\n2. Vascular lab evidence of PAD (such as a toe brachial pressure \\\u003C= 0.70 or an ankle brachial index less than or equal to 0.90), or angiographic evidence of PAD defined as at least 70% stenosis of an artery supplying the lower extremities.\n3. An ABI of \\>0.90 and \\\u003C= 1.00 who experience a 20% or greater drop in ABI in either leg after the heel-rise test.\n\nExclusion Criteria:\n\n1. Above- or below-knee amputation\n2. Critical limb ischemia defined as an ABI \\\u003C0.40 with symptoms of rest pain\n3. Wheelchair confinement or requiring a walker to ambulate\n4. Walking is limited by a symptom other than PAD\n5. Current foot ulcer on bottom of foot\n6. Failure to successfully complete the study run-in\n7. Planned major surgery, coronary or leg revascularization during the next four months\n8. Major surgery, coronary or leg revascularization or major cardiovascular event in the previous three months\n9. Major medical illness including lung disease requiring oxygen, Parkinson's disease, a life-threatening illness with life expectancy less than six months, or cancer requiring treatment in the previous two years. \\[NOTE: potential participants may still qualify if they have had treatment for an early stage cancer in the past two years and the prognosis is excellent, unless the cancer is located in the lower extremities. Participants who require oxygen only at night may still qualify.\\]\n10. Mini-Mental Status Examination (MMSE) score \\\u003C 23\n11. Non-English speaking\n12. Participation in or completion of a clinical trial in the previous three months. \\[NOTE: after completing a stem cell or gene therapy intervention, participants will become eligible after the final study follow-up visit of the stem cell or gene therapy study so long as at least six months have passed since the final intervention administration. After completing a supplement or drug therapy (other than stem cell or gene therapy), participants will be eligible after the final study follow-up visit as long as at least three months have passed since the final intervention of the trial.\\]\n13. Visual impairment that limits walking ability.\n14. Six-minute walk distance of \\\u003C400 feet or \\>1700 feet.\n15. Participation in a supervised treadmill exercise program or a cardiac rehabilitation program in previous three months or planning to begin a supervised treadmill exercise program or a cardiac rehabilitation program in the next five months.\n16. Unwilling to avoid red light therapy outside of study participation.\n17. Baseline blood pressure \\\u003C100\u002F45.\n18. In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant.","50 Years",{"count":61,"type":20},32,[23],"The ENLIGHTEN PAD Trial will collect preliminary data to test whether daily 660 nm light treatment of the lower extremities immediately before home-based walking exercise sessions improves six-minute walk distance at 4-month follow-up, compared to sham light, in people with lower extremity peripheral artery disease (PAD).",[65,26,66,67],"Peripheral Artery Disease","Aging","Walking, Difficulty",[69,70,71],"light therapy","peripheral artery disease","exercise","2026-04-11",{"date":74,"type":42},"2026-04-15",{"date":76,"type":42},"2024-08-12",{"date":78,"type":20},"2027-01-31",{"name":80,"class":81},"Northwestern University","OTHER",1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":91,"maxAge":4,"enrollmentInfo":92,"targetDuration":94,"studyType":95,"phases":4,"briefSummary":96,"conditions":97,"keywords":98,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":82},"100631433","observing-the-role-of-inflammation-in-peripheral-artery-disease-and-its-impact-on-heart-and-mobility-health-panacea-o-100631433","NCT07500610","Observing the Role of Inflammation in Peripheral Artery Disease and Its Impact on Heart and Mobility Health: PANACEA-O.","Protocol Title Peripheral Arterial Disease and InflammatioN Study Assessing the Cardiovascular and Functional Effects - Observational Study: PANACEA-O","PANACEA-O","Inclusion Criteria:\n\n* Age \\>\u002F= 19 years of age\n* Ability to provide informed consent before any trial-related activities\n* Symptomatic PAD with intermittent claudication corresponding to Fontaine stage IIa meeting all of the following:\n\n  1. Stable symptoms of PAD with intermittent claudication in Fontaine stage IIa (able to walk without stopping more than 200 m\u002F656 feet\u002F2 blocks) for at least 90 days prior to the day of screening based on patient interview.\n  2. Ankle-brachial-index (ABI) equal to or below 0.90 (the leg with lowest index is chosen in case of bilateral disease) or ≥ 50% stenosis in peripheral artery (excluding carotid) documented by X-ray angiography, MR angiography, CT angiography or Doppler ultrasound, or a history of lower extremity revascularization\n\nExclusion Criteria:\n\n* Current or previous treatment with any immunomodulating agent within 90 days prior to the day of screening.\n* Walking ability limited by conditions other than PAD\n* Planned orthopaedic surgery in the legs, or other major surgery known on the day of screening (surgery affecting walking ability).\n* Vascular revascularisation procedure for PAD of any kind 180 days prior to the day of screening.\n* Planned arterial revascularisation known on the day of screening.\n* Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischemic attack within 180 days prior to the day of screening.\n* Heart failure presently classified as being in New York Heart Association (NYHA) class III-IV.\n* Signs\u002Fsymptoms of critical limb ischemia (leg gangrene, rest pain, ischemic wounds, etc)","19 Years",{"count":93,"type":20},50,"1 Day","OBSERVATIONAL","This registry aims to collect detailed information about people in Canada who have Peripheral Artery Disease (PAD) and are receiving care in heart clinics while still able to walk and live in the community. Researchers want to better understand what these patients are like at the start of their care and looking at their general health, levels of inflammation in their bodies, and how well they can move and function in daily life.\n\nThe results of this study will help healthcare providers better understand what PAD looks like in today's Canadian heart clinics. It will also help guide future research studies that focus on inflammation and PAD. The researchers believe that PAD patients can be routinely recruited from these clinics, and that most of these patients will have high levels of inflammation (shown by high blood CRP levels) and poor physical ability when they first join. The findings will show that there is a strong need to regularly check for PAD in heart clinics so that patients can be identified early and offered new treatments in the future and especially treatments that may help reduce inflammation.",[26],[99,100,101,102,103],"peripheral vascular disease","inflammation","CRP","claudication","ABI","2026-03-25",{"date":106,"type":42},"2026-03-30",{"date":108,"type":42},"2025-09-25",{"date":110,"type":20},"2026-07",{"name":112,"class":81},"Cardiology Research UBC",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":119,"sex":16,"minAge":120,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":21,"phases":124,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":82},"100545993","leg-exercise-assistive-paddling-leap-therapy-for-peripheral-artery-disease-100545993","NCT06389149","Leg Exercise Assistive Paddling (LEAP) Therapy for Peripheral Artery Disease","Inclusion Criteria:\n\nPAD subjects:\n\n* Able to provide written informed consent\n* 50-85 years of age\n* Diagnosed with Peripheral Arterial Disease (PAD) Fontaine stage II-III\n* Women must be postmenopausal (cessation of menses for \\> 24 months)\n* History of exercise-induced claudication\n* Free of ulcers, gangrene, or necrosis of the foot, Fontaine stage IV PAD\n\nAge-matched control subjects:\n\n* Able to provide written informed consent\n* 50-85 years of age\n* No evidence of peripheral occlusive disease, ankle-brachial index \\> 0.90\n* Women must be postmenopausal (cessation of menses for \\> 24 months)\n\nExclusion Criteria:\n\nPAD subjects:\n\n* Pain at rest and\u002For tissue loss from Peripheral Arterial Disease (PAD), Fontaine stage IV PAD\n* Acute lower extremity ischemic event secondary to thromboembolic disease or acute trauma\n* Limited walking capacity from conditions other than PAD\n* Have not had a physical exam to assess exercise limitations in the past year\n* Pregnant or nursing\n* Kidney disease or type II diabetes mellitus\n\nAge-matched control subjects:\n\n* Positive diagnosis of Peripheral Arterial Disease (PAD)\n* Any exercise limitations as determined at last physical exam, at least 1 year prior to study\n* Have not had a physical exam to assess exercise limitations in the past year\n* Limited walking capacity from musculoskeletal injury\n* Pregnant or nursing\n* Kidney disease or type II diabetes mellitus",true,"55 Years","85 Years",{"count":123,"type":20},24,[23],"The purpose of this study is to test the effects of leg exercise assistive paddling (LEAP) therapy during prolonged sitting (PS) on vascular and functional performance in those with peripheral artery disease (PAD) and age-matched controls. LEAP therapy is a novel application of passive limb movement to enhance blood flow through the legs without muscular contractions. Specifically, LEAP therapy is the rotational passive movement of the lower leg about the knee from 90 to 180 degrees of rotation at a cadence of 1Hz. Previous literature has indicated that this movement pattern can produce robust increases in blood flow in the passively moved limb in healthy individuals, and passive limb movement may protect vascular function during PS. However, the impact of LEAP therapy to improve blood flow in the legs of those with PAD during PS is unknown.\n\nParticipants will participate in a randomized cross-over design study with 2 visits (LEAP therapy and no LEAP therapy). For the first visit, participants will be randomly allocated to receive LEAP therapy during 2.5 hours of PS or not. For the second visit, participants will sit for 2.5 hours and will receive the condition that they did not previously receive. Before and after PS, the following measurements will be made: flow-mediated dilation of the popliteal and brachial arteries, arterial stiffness with tonometry techniques, microvascular vasodilatory capacity and skeletal muscle metabolic rate with near-infrared spectroscopy, autonomic nervous system function, and there will be blood drawn from the antecubital vein. After PS, participants will participate in a graded exercise test to assess functional walking capacity. Finally, during PS, near-infrared spectroscopy on the calf muscles and electrocardiogram will be collected continuously to monitor muscle oxygen availability and autonomic activity, respectively.",[27,26,127,65],"Peripheral Artery Occlusive Disease","2025-09-29",{"date":130,"type":42},"2025-10-01",{"date":132,"type":42},"2024-08-16",{"date":134,"type":20},"2026-08",{"name":136,"class":81},"University of Nebraska",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":21,"phases":147,"briefSummary":149,"conditions":150,"keywords":154,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":169},"100568814","phase-3-improving-mobility-after-revascularization-in-peripheral-artery-disease-100568814","NCT06686121","Improving Mobility After Revascularization in Peripheral Artery Disease","IMProving Mobility After revasCularizaTion in Peripheral Artery Disease: The IMPACT PAD Trial","IMPACT PAD","Inclusion Criteria:\n\nSuccessful lower extremity revascularization for disabling PAD performed at least 30 days before baseline testing and between 30 and 100 days before randomization.\n\nExclusion Criteria:\n\n1. History of leg amputation, not including toe and partial foot amputation\n2. Active gangrene\n3. Active limb threatening ischemia\n4. Already exercising at a level consistent with exercise intervention, using investigator discretion.\n5. Unstable angina\n6. Unwilling to drink study beverages\n7. Unwilling to adhere to the interventions and complete follow-up testing\n8. Currently taking sildenafil, tadalafil, or related drugs.\n9. Unwilling to accept randomization into either group (home-based exercise or attention control)\n10. Currently consuming beetroot juice, oral nitrate or nitrite, or a beetroot supplement and\u002For unwilling to avoid beetroot juice during the study. Participants will be asked to discontinue these items for 30 days before baseline testing and throughout the clinical trial. If the potential participant is unwilling to refrain from taking these items, they will not be eligible for the clinical trial.\n11. History of kidney stones that requires minimized intake of oxalate. Potential participants who need to minimize oxalate intake will be excluded from the trial.\n12. Baseline blood pressure \\\u003C100\u002F45.\n13. Wheelchair confinement or requiring a walker to ambulate\n14. Walking is limited by a condition other than PAD\n15. Current foot ulcer\n16. Planned major surgery, coronary revascularization, or lower extremity revascularization during the next 12 months\n17. Major medical illness including lung disease requiring oxygen, Parkinson's disease, or a life-threatening illness with life expectancy less than six months.\n18. Allergy to beetroot juice\n19. Currently consuming one cup or more of beets daily. Participants will be asked to decrease beet consumption to less than one cup of beets per day for 14 days before baseline testing and throughout the clinical trial. If the potential participant is unwilling to refrain from daily beet consumption of one cup or more for 30 days before the trial and during the trial, they will not be eligible for the clinical trial.\n20. Participation in or completion of a clinical trial in the previous three months, using investigator discretion for trials that may not impact study participation or outcome measures of the IMPACT PAD Trial.\n21. Visual impairment that limits walking ability.\n22. Unable to communicate in English, unless the participant communicates in Spanish and is enrolled at a site that can deliver the intervention in Spanish. All sites with a Spanish speaking coordinator and interventionist will be able to enroll Spanish-speaking participants. While investigators aim to be as inclusive as possible, resources are not available to allow inclusion of people speaking languages that are not Spanish or English.\n23. Using a mouthwash containing chlorhexidine or cetylpyridinium chloride or a mouthwash determined to be bactericidal and unwilling to discontinue.\n24. Planning to begin a supervised treadmill exercise program in the next 12 months.\n25. Heart attack or stroke in previous three months prior to baseline testing.\n26. In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant.",{"count":146,"type":20},386,[148],"PHASE3","Lower extremity revascularization combined with supervised exercise significantly improves walking performance compared to revascularization alone in people who have PAD without limb threatening ischemia. However, supervised exercise is inaccessible or burdensome for most PAD patients. Investigators hypothesize that home-based exercise combined with lower extremity revascularization will significantly improve walking performance compared to revascularization alone in patients with PAD undergoing revascularization for disabling PAD.\n\nInvestigators further hypothesize that inorganic nitrate, a major source of nitric oxide (NO) abundant in beetroot juice, will improve walking performance after lower extremity revascularization, compared to placebo. In preclinical models, NO inhibits inflammation, neointimal hyperplasia, thrombosis, and vascular smooth muscle cell migration at sites of revascularization. NO increases angiogenesis and perfusion, repairs skeletal muscle damaged by ischemia, and stimulates mitochondrial activity.\n\nIn a randomized clinical trial with a 2 x 2 factorial design, the trial will test the following two primary hypotheses in 386 patients randomized within three months of a successful lower extremity revascularization for disabling PAD: First, that home-based exercise combined with lower extremity revascularization will improve six-minute walk distance more than revascularization alone at 6-month follow-up (Primary Aim #1). Second, that nitrate-rich beetroot juice combined with lower extremity revascularization will improve six-minute walk, compared to placebo combined with revascularization at 6-month follow-up (Primary Aim #2).",[65,151,26,152,153],"Intermittent Claudication","Mobility Limitation","Revascularization",[155,156,157,153,158,29,159,160],"Behavior Change","Patient Reported Outcome Measures","Mobility","Peripheral artery disease","6-minute walk","Oxidative stress","2025-08-23",{"date":163,"type":42},"2025-08-26",{"date":165,"type":42},"2025-08-04",{"date":167,"type":20},"2032-08-01",{"name":80,"class":81},7,{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":16,"minAge":178,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":21,"phases":181,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":189,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":82},"100563209","phase-4-colonoscopy-and-antiplatelet-therapy-trial-100563209","NCT06613191","Colonoscopy and Antiplatelet Therapy Trial","P2Y12 Inhibitor Versus Aspirin Monotherapy in Patients Undergoing Elective Screening and Surveillance Colonoscopy","CAPTT","Inclusion Criteria:\n\n1. Age ≥ 45 years\n2. Stable patients defined as having Angina CCS (Canadian Cardiovascular Society) class 1-3 and\u002For Heart Failure NYHA class 1-2 without a change in guideline directed anti-ischemic or heart failure medications within 30 days prior to randomization.\n3. Patients with cardiovascular disease defined as coronary artery disease, cerebrovascular disease or peripheral vascular disease taking DAPT (defined as aspirin plus a P2Y12 inhibitor). The decision to use DAPT in this patient will be made by the managing physician(s) before recruitment for this study. Consider replacing last statement with \"As directed by their physician prior to recruitment into this study\"\n4. Scheduled for elective screening or surveillance outpatient colonoscopy\n\nExclusion Criteria:\n\n1. Coronary intervention (PCI or CABG) less than 90 days prior to randomization\n2. ACS event in less than 90 days prior to randomization\n3. Transient ischemic attack (TIA) and\u002For stroke event in less than 90 days prior to randomization\n4. Acute limb ischemia and\u002For amputation in less than 90 days prior to randomization\n5. Post cardiac valve replacement (either percutaneous or surgical)\n6. High cardiovascular risk:\n\n   1. Patients with CCS class 4 angina\n   2. Hospitalized with ACS within 1 month prior to randomization\n   3. Patients undergoing PCI or CABG within the 3 months prior to randomization\n7. Patients on left ventricular assist device (LVAD) or post cardiac transplantation\n8. Patients with NYHA class 3 or 4 heart failure\n9. Any condition requiring treatment requires chronic use of an anticoagulant.\n10. Chronic kidney disease Stage 5 (with or without dialysis)\n11. Liver cirrhosis with platelet count \\< 50,000\u002F mm3 and\u002For INR \\>1.4\n12. Hematocrit \\< 30% and hemoglobin \\< 10 mg\u002FdL\n13. Emergent or inpatient Colonoscopy","45 Years",{"count":180,"type":20},100,[182],"PHASE4","Patients on dual antiplatelet therapy )aspirin plus a P2Y12 inhibitor \\[clopidogrel, prasugrel, or ticagrelor\\]) undergoing screening or surveilance colonoscopy are at increased risk for bleeding from the procedure. Patients are ussually asked to stop the P2Y12 inhibitor for the procedure. Currently, recommendation is that patients only on a P2Y12 inhibitor be changes to aspirin for the procedure. This pilot study will evaluate if there is a large difference in bleeding between patients only taking aspirin compared with patients only taking a P2Y12 inhibitor. Patinets who participate will randomly be randomly asked to stop either aspirin or the P2Y12 inhibitor 1 week before the procedure. Periprocedural bleeding and bleeding after the procedure for iup to 30 days.",[185,26],"Coronary Arterial Disease (CAD)",[187,188],"Colonoscopy","Antiplatelet therapy","NOT_YET_RECRUITING","2024-09-23",{"date":192,"type":42},"2024-09-25",{"date":194,"type":20},"2024-10-01",{"date":196,"type":20},"2026-06-30",{"name":198,"class":81},"Ochsner Health System",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":206,"enrollmentInfo":207,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":209,"conditions":210,"keywords":213,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":82},"100535552","treatment-of-tasc-c-and-d-aortoiliac-lesions-100535552","NCT06253312","Treatment of TASC C and D Aortoiliac Lesions","Comparison of Open Surgery, Hybrid and Endovascular Repair for Complex TASC C\u002FD Aortoiliac Lesions","Inclusion Criteria:\n\n* All patients (over 18 years of age) with a history of atherosclerotic peripheral arterial disease treated between 1st January 2015 and 1st January 2022\n* All management strategies will be included (endovascular, hybrid, and open)\n\nExclusion Criteria:\n\n* Patients who are pregnant\n* Patients who are under 18 years of age\n* Patients who have acute limb ischemia or acute on chronic ischemia\n* Non-atherosclerotic origin of disease: cyclist disease, trauma, dissection\n* Patients who were treated in conservative manner\n* Patients who underwent primary major amputation\n* Patients with limited life expectancy (less than 2 years)","100 Years",{"count":208,"type":20},900,"Background:\n\nThe treatment of patients with complex aortoiliac disease (AID), classified as Trans-Atlantic Inter-Society consensus II (TASC) class C and D, presents a dilemma for vascular surgeons. Current guidelines recommend either open surgical reconstruction (OR), hybrid repair (HR) combining iliac stenting with femoral endarterectomy, or total endovascular repair (ER). While traditional OR with aortobifemoral bypass (ABF) is associated with excellent long term patency results, it is associated with significant perioperative morbidity with some studies citing mortality rates of up to 4-8%. The advancement of endovascular techniques has led to many trials suggesting that endovascular management of TASC II C and D lesions is a potential alternative treatment to open strategies mainly in the subset of patients with high surgical risk, given the substantially less perioperative morbidity and mortality compared to OR.\n\nAim:\n\nThe aim of this trial is to evaluate the short, mid-, and long-term results of open repair, hybrid and endovascular repair in the treatment patients with complex, TASC C and D, aortoiliac lesions.\n\nMethodology:\n\nThis is a retrospective cohort study planning to include vascular surgery centers from the following countries: Italy, Portugal, Spain, and Serbia. Data will be collected on demographics, baseline comorbidities, anatomy and morphology of the aortoiliac and femoral bifurcation disease, intraoperative, postoperative, and follow-up data. Propensity score analysis will be performed by matching open repair patients in all three groups (open, hybrid, and endovascular repair) controlling for demographics, baseline comorbidities, anatomical and morphological data.\n\nEndpoints:\n\nPrimary endpoints are all-cause mortality and the major adverse limb events (major amputation - below and above the knee, new onset acute limb ischaemia, reintervention of the treated arterial segment). The secondary endpoints are the 30-day complications and primary patency.",[27,211,212,26],"Aortoiliac Occlusive Disease","Leriche Syndrome",[214,215,216,217,218,219,220],"peripheral arterial disease","aortoiliac disease","TASC C,D","open surgery","hybrid repair","endovascular repair","atherosclerosis","2024-08-21",{"date":223,"type":42},"2024-08-23",{"date":225,"type":42},"2024-05-01",{"date":227,"type":20},"2025-09-01",{"name":229,"class":81},"Clinical Centre of Serbia",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":16,"minAge":238,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":241,"conditions":242,"keywords":4,"overallStatus":189,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":4},"100552444","mobility-assessment-in-multi-morbidity-100552444","NCT06473168","Mobility Assessment in Multi-morbidity","Walking-related Mobility Assessment in Older People With Multimorbidity","Multi-mobility","Inclusion Criteria:\n\n* Adults ≥65 years old\n* Able and willing to provide informed consent\n* Able to read and write in English\n* To be mobile (including the use of walking aids)\n* Two or more of the following long terms conditions: Arthritis, Asthma, Atrial fibrillation, Bronchiectasis, Cancer, Chronic kidney disease, Chronic obstructive pulmonary disease, Coronary heart disease, Anxiety, Depression, Diabetes mellitus, Heart failure, Hypertension, Osteoporosis, Parkinson's disease, Peripheral vascular disease, Stroke or transient ischaemic attack\n\nExclusion Criteria:\n\n* Unable to give consent for the study\n* Severe mental health problems\n* Active malignancy (on chemotherapy\u002Fradiotherapy\u002Fplanned urgent surgery)","65 Years",{"count":240,"type":20},55,"Multimorbidity (the presence of two or more coexisting long-term conditions) is a significant challenge facing the NHS, especially given UK's ageing population and the association with high levels of illness burden and healthcare costs. Over 50% of adults \\>65 years have multiple long-term conditions (MLTCs).\n\nOur group has validated a broad range of algorithms applied to single wearable sensors that have the potential to capture walking-related mobility outcomes (such as walking cadence and walking speed) accurately and reliably during activities of daily living across five single long-term conditions. These algorithms, however, cannot be readily applied to people with MLTCs because the effect of multimorbidity on mobility is amplified compared to single long-term conditions secondary to a greater number of complications and sequelae. Accordingly, the aim of this study is to validate algorithms that would allow robust estimation of walking-related mobility outcomes during daily life activities in MLTCs.\n\nTo meet our objectives, the investigators will perform: i) laboratory-based technical validation of existing and newly developed algorithms for walking-related mobility outcome detection; ii) unsupervised real-life validation of selected algorithms; and iii) examination of how well the validated walking-related mobility outcomes reflect global and disease specific characteristics in older adults with multimorbidity. The investigators will adopt an integrated patient-centric approach where patients with MLTCs will be engaged early in the project to provide input of their perception and concerns regarding mobility limitation in daily life activities.\n\nThe investigators aim to recruit 55 older adults (\\>65 years), men and women, with multiple long-term conditions with the following inclusion criteria: having two or more of the following conditions including osteoarthritis, rheumatoid arthritis, osteoporosis, type 2 diabetes, depression and\u002For anxiety, hypertension, coronary heart disease, heart failure, atrial fibrillation, chronic obstructive pulmonary disease, asthma, bronchiectasis, chronic kidney disease, cancer, or stroke within the last 5 years.",[243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,26,258,259],"Arthritis","Asthma","Atrial Fibrillation","Bronchiectasis","Cancer","Chronic Kidney Diseases","Chronic Obstructive Pulmonary Disease","Coronary Heart Disease","Anxiety","Depression","Diabetes Mellitus","Heart Failure","Hypertension","Osteoporosis","Parkinson Disease","Stroke","Transient Ischemic Attack","2024-06-18",{"date":262,"type":42},"2024-06-25",{"date":264,"type":20},"2024-12-01",{"date":266,"type":20},"2025-12-31",{"name":268,"class":81},"Northumbria University"]